制定遗传性鱼鳞病(COSII)核心结局集的方案。

IF 3 3区 医学 Q2 DERMATOLOGY
Dermatology Pub Date : 2025-04-29 DOI:10.1159/000546035
Vanya S V J Rossel, Jason Shourick, Maria C Bolling, Anna M G Pasmooij, Karin Veldman, Jamie J Kirkham, Juliette Mazereeuw-Hautier, Antoni H Gostyński
{"title":"制定遗传性鱼鳞病(COSII)核心结局集的方案。","authors":"Vanya S V J Rossel, Jason Shourick, Maria C Bolling, Anna M G Pasmooij, Karin Veldman, Jamie J Kirkham, Juliette Mazereeuw-Hautier, Antoni H Gostyński","doi":"10.1159/000546035","DOIUrl":null,"url":null,"abstract":"<p><p>Introduction Inherited ichthyosis comprise a group of rare keratinization disorders caused by abnormal epidermal barrier function. Ichthyosis is yet incurable and current treatments mainly focus on alleviating symptoms such as scaling, erythema and pruritus. Recent developments show promising results for interventions based on the immune-phenotype like biologicals or pathogenesis-based therapies such as gene therapy. However, the lack of uniform reporting and variety of treatment outcomes may complicate performing and comparing efficacy studies. The core outcome set for inherited ichthyosis (COSII) aims to develop a core outcome set (COS), i.e. the minimum of outcomes that should be measured and reported in effectiveness research, including a minimum set of baseline characteristics. Methods The COSII project will follow the guidelines from the Core Outcome Measures in Effectiveness Trials (COMET) initiative including the Core Outcome Set-STAndards for Development (COS-STAD) recommendations and the Core Outcome Set Standardised Protocol (COS-STAP) checklist. The COS development methodology, including this protocol, follows guidance of the CHORD COUSIN Collaboration 'C3'. The first stage of this project involves identifying a possible list of outcomes through performing a scoping literature review and conducting interviews with patient(s) (representatives). This list will be presented to five different stakeholders groups: healthcare professionals, researchers, patient(s) (representatives), industry representatives and regulators. All stakeholders will rate the importance of each outcome in a three-round eDelphi survey. Ultimately, a virtual consensus meeting will be convened to finalize the COS. Ethical approval was obtained prior to the start of this project from the Medical Ethics Committee board at Maastricht University Medical Centre (METC 2022-3192). Informed consent will be asked prior to enrolment in the eDelphi. This study is registered with the COMET. The results will be distributed via a peer-reviewed journal, communicated to all relevant parties and showcased at national and international conferences. Conclusion This will be the first COS for inherited ichthyosis research in accordance with the Core Outcome Measures in Effectiveness Trials initiative. The development of a COS aims to improve consistency of reporting and the heterogeneity of outcomes in ichthyosis research.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Protocol for the development of a Core Outcome Set for Inherited Ichthyosis (COSII).\",\"authors\":\"Vanya S V J Rossel, Jason Shourick, Maria C Bolling, Anna M G Pasmooij, Karin Veldman, Jamie J Kirkham, Juliette Mazereeuw-Hautier, Antoni H Gostyński\",\"doi\":\"10.1159/000546035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Introduction Inherited ichthyosis comprise a group of rare keratinization disorders caused by abnormal epidermal barrier function. Ichthyosis is yet incurable and current treatments mainly focus on alleviating symptoms such as scaling, erythema and pruritus. Recent developments show promising results for interventions based on the immune-phenotype like biologicals or pathogenesis-based therapies such as gene therapy. However, the lack of uniform reporting and variety of treatment outcomes may complicate performing and comparing efficacy studies. The core outcome set for inherited ichthyosis (COSII) aims to develop a core outcome set (COS), i.e. the minimum of outcomes that should be measured and reported in effectiveness research, including a minimum set of baseline characteristics. Methods The COSII project will follow the guidelines from the Core Outcome Measures in Effectiveness Trials (COMET) initiative including the Core Outcome Set-STAndards for Development (COS-STAD) recommendations and the Core Outcome Set Standardised Protocol (COS-STAP) checklist. The COS development methodology, including this protocol, follows guidance of the CHORD COUSIN Collaboration 'C3'. The first stage of this project involves identifying a possible list of outcomes through performing a scoping literature review and conducting interviews with patient(s) (representatives). This list will be presented to five different stakeholders groups: healthcare professionals, researchers, patient(s) (representatives), industry representatives and regulators. All stakeholders will rate the importance of each outcome in a three-round eDelphi survey. Ultimately, a virtual consensus meeting will be convened to finalize the COS. Ethical approval was obtained prior to the start of this project from the Medical Ethics Committee board at Maastricht University Medical Centre (METC 2022-3192). Informed consent will be asked prior to enrolment in the eDelphi. This study is registered with the COMET. The results will be distributed via a peer-reviewed journal, communicated to all relevant parties and showcased at national and international conferences. Conclusion This will be the first COS for inherited ichthyosis research in accordance with the Core Outcome Measures in Effectiveness Trials initiative. The development of a COS aims to improve consistency of reporting and the heterogeneity of outcomes in ichthyosis research.</p>\",\"PeriodicalId\":11185,\"journal\":{\"name\":\"Dermatology\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000546035\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546035","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

遗传性鱼鳞病是由表皮屏障功能异常引起的一组罕见的角化疾病。鱼鳞病是无法治愈的,目前的治疗主要集中在减轻症状,如鳞屑,红斑和瘙痒。最近的发展表明,基于免疫表型的干预措施(如生物制剂)或基于致病机制的治疗(如基因治疗)都有希望取得成果。然而,缺乏统一的报告和治疗结果的多样性可能会使疗效研究的实施和比较复杂化。遗传性鱼鳞病(COSII)的核心结果集旨在制定一个核心结果集(COS),即在有效性研究中应测量和报告的最小结果集,包括一组最小基线特征。方法COSII项目将遵循有效性试验核心结果测量(COMET)倡议的指导方针,包括发展核心结果集标准(COS-STAD)建议和核心结果集标准化方案(COS-STAP)清单。COS开发方法,包括本协议,遵循CHORD COUSIN协作“C3”的指导。该项目的第一阶段包括通过进行范围文献综述和与患者(代表)进行访谈来确定可能的结果列表。这份清单将提交给五个不同的利益相关者群体:医疗保健专业人员、研究人员、患者代表、行业代表和监管机构。所有利益相关者将在三轮eDelphi调查中评估每个结果的重要性。最后,将召开一次虚拟协商一致会议,以最后确定COS。在该项目开始之前,已获得马斯特里赫特大学医学中心医学伦理委员会委员会(METC 2022-3192)的伦理批准。在参加eDelphi之前,将征求知情同意。这项研究已在彗星注册。研究结果将通过同行评议的期刊发布,传达给所有相关方,并在国内和国际会议上展示。根据有效性试验的核心结局指标,这将是遗传性鱼鳞病研究的第一个COS。COS的发展旨在提高鱼鳞病研究报告的一致性和结果的异质性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Protocol for the development of a Core Outcome Set for Inherited Ichthyosis (COSII).

Introduction Inherited ichthyosis comprise a group of rare keratinization disorders caused by abnormal epidermal barrier function. Ichthyosis is yet incurable and current treatments mainly focus on alleviating symptoms such as scaling, erythema and pruritus. Recent developments show promising results for interventions based on the immune-phenotype like biologicals or pathogenesis-based therapies such as gene therapy. However, the lack of uniform reporting and variety of treatment outcomes may complicate performing and comparing efficacy studies. The core outcome set for inherited ichthyosis (COSII) aims to develop a core outcome set (COS), i.e. the minimum of outcomes that should be measured and reported in effectiveness research, including a minimum set of baseline characteristics. Methods The COSII project will follow the guidelines from the Core Outcome Measures in Effectiveness Trials (COMET) initiative including the Core Outcome Set-STAndards for Development (COS-STAD) recommendations and the Core Outcome Set Standardised Protocol (COS-STAP) checklist. The COS development methodology, including this protocol, follows guidance of the CHORD COUSIN Collaboration 'C3'. The first stage of this project involves identifying a possible list of outcomes through performing a scoping literature review and conducting interviews with patient(s) (representatives). This list will be presented to five different stakeholders groups: healthcare professionals, researchers, patient(s) (representatives), industry representatives and regulators. All stakeholders will rate the importance of each outcome in a three-round eDelphi survey. Ultimately, a virtual consensus meeting will be convened to finalize the COS. Ethical approval was obtained prior to the start of this project from the Medical Ethics Committee board at Maastricht University Medical Centre (METC 2022-3192). Informed consent will be asked prior to enrolment in the eDelphi. This study is registered with the COMET. The results will be distributed via a peer-reviewed journal, communicated to all relevant parties and showcased at national and international conferences. Conclusion This will be the first COS for inherited ichthyosis research in accordance with the Core Outcome Measures in Effectiveness Trials initiative. The development of a COS aims to improve consistency of reporting and the heterogeneity of outcomes in ichthyosis research.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dermatology
Dermatology 医学-皮肤病学
CiteScore
6.40
自引率
2.90%
发文量
71
审稿时长
1 months
期刊介绍: Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信